A peptide corresponding to the neuropilin-1-binding site on VEGF165 induces apoptosis of neuropilin-1-expressing breast tumour cells

There is increasing evidence that vascular endothelial growth factor (VEGF) has autocrine as well as paracrine functions in tumour biology. Vascular endothelial growth factor-mediated cell survival signalling occurs via the classical tyrosine kinase receptors Flt-1, KDR/Flk-1 and the more novel neuropilin (NP) receptors, NP-1 and NP-2. A 24-mer peptide, which binds to neuropilin-1, induced apoptosis of murine and human breast carcinoma cells, whereas a peptide directed against KDR had no effect. Both anti-NP1 and anti-KDR peptides induced endothelial cell apoptosis. Confocal microscopy using 5-(6)-carboxyfluorescein-labelled peptides showed that anti-NP1 bound to both tumour and endothelial cells, whereas anti-KDR bound endothelial cells only. This study demonstrates that NP-1 plays an essential role in autocrine antiapoptotic signalling by VEGF in tumour cells and that NP1-blockade induces tumour cell and endothelial cell apoptosis. Specific peptides can therefore be used to target both autocrine (tumour cells) and paracrine (endothelial cells) signalling by VEGF.

[1]  L. Shaw,et al.  Advances in Brief Vascular Endothelial Growth Factor Is an Autocrine Survival Factor for Neuropilin-expressing Breast Carcinoma Cells 1 , 2001 .

[2]  L. Williams,et al.  Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Shibuya,et al.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.

[4]  R. Bachelder,et al.  Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. , 2002, Cancer research.

[5]  A. Ullrich,et al.  Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. , 1996, Cancer research.

[6]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[7]  Tae-Hee Lee,et al.  Vascular Endothelial Growth Factor Modulates the Transendothelial Migration of MDA-MB-231 Breast Cancer Cells through Regulation of Brain Microvascular Endothelial Cell Permeability* , 2003, The Journal of Biological Chemistry.

[8]  Shay Soker,et al.  Characterization of Novel Vascular Endothelial Growth Factor (VEGF) Receptors on Tumor Cells That Bind VEGF via Its Exon 7-encoded Domain (*) , 1996, The Journal of Biological Chemistry.

[9]  Nijole Gasiunas,et al.  Neuropilin-1 Binds Vascular Endothelial Growth Factor 165, Placenta Growth Factor-2, and Heparin via Its b1b2 Domain* , 2002, The Journal of Biological Chemistry.

[10]  D. Bouchier-Hayes,et al.  Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells , 2001, British Journal of Cancer.

[11]  R K Jain,et al.  Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[13]  G. Neufeld,et al.  Neuropilin-2 and Neuropilin-1 Are Receptors for the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF) and of Placenta Growth Factor-2, but Only Neuropilin-2 Functions as a Receptor for the 145-Amino Acid Form of VEGF* , 2000, The Journal of Biological Chemistry.

[14]  B. Eickholt,et al.  Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. , 2003, Cancer research.

[15]  P. Singhal,et al.  Morphine promotes apoptosis in Jurkat cells , 1999, Journal of leukocyte biology.

[16]  J. Harmey,et al.  Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[17]  S. Soker,et al.  Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Poo,et al.  Plexins Are a Large Family of Receptors for Transmembrane, Secreted, and GPI-Anchored Semaphorins in Vertebrates , 1999, Cell.

[19]  M. Lohrum,et al.  Plexin/neuropilin complexes mediate repulsion by the axonal guidance signal semaphorin 3A , 2000, Mechanisms of Development.

[20]  S. Soker,et al.  Inhibition of Vascular Endothelial Growth Factor (VEGF)-induced Endothelial Cell Proliferation by a Peptide Corresponding to the Exon 7-Encoded Domain of VEGF165 * , 1997, The Journal of Biological Chemistry.

[21]  T. Kitsukawa,et al.  Receptors for collapsin/semaphorins , 1998, Current Opinion in Neurobiology.

[22]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[23]  S. Strittmatter,et al.  PlexinA1 Autoinhibition by the Plexin Sema Domain , 2001, Neuron.

[24]  J. Wood,et al.  Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. , 2000, International journal of oncology.

[25]  R. Weichselbaum,et al.  Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation , 1999 .

[26]  C. Demangel,et al.  Identification of a peptide blocking vascular endothelial growth factor (VEGF)‐mediated angiogenesis , 2000, The EMBO journal.